Formulation and specifications: Capsules: 8mg, 10mg, 12mg
Indications:
1. This drug alone is indicated for the treatment of patients with locally advanced or metastatic NSCLC who have progressed or relapsed after receiving at least 2 prior systemic chemotherapies. For patients with EGFR mutations or ALK positivity, progression or relapse after treatment with appropriate targeted agents and after at least 2 prior systemic chemotherapies should be received prior to initiation of this product.
2. This drug alone is indicated for the treatment of patients with small cell lung cancer who have progressed or relapsed after receiving at least 2 prior chemotherapy regimens.
Key points for rational drug use:
1. Genetic testing is not required prior to the use of anlotinib, but for patients with EGFR gene mutations or positive ALK fusions, progression or relapse after treatment with the appropriate standard targeted agent and after at least 2 prior systemic chemotherapy regimens should be received prior to initiation of anlotinib therapy.
2. Contraindicated in patients with central squamous cell carcinoma of the lung or at risk of massive hemoptysis, or in patients with severe hepatic or renal impairment.
Anlotinib is associated with an increased risk of bleeding events and thrombotic/embolic events; therefore, it should be used with caution in patients at risk for bleeding, abnormal coagulation, patients with a history of thrombosis/stroke, and patients taking anticoagulants and related conditions.
4. The recommended dose is 12 mg once daily by mouth before breakfast for 2 weeks and 1 week off, i.e. 3 weeks as a course of treatment. The dose should be closely monitored for adverse reactions and adjusted under the guidance of physicians according to the degree of adverse reactions.
5. The occurrence of hypertension should be closely monitored during the drug administration. Conventional antihypertensive drugs can effectively control the patient’s blood pressure, such as thiazide diuretics, angiotensin-converting enzyme inhibitors (ACEI), etc. (In view of drug interactions, calcium antagonists can be selected as appropriate for hypertension that cannot be controlled by ACEI class).
6. Avoid combination with strong inhibitors and strong inducers of CYP1A2 and CYP3A4.